Physician profile
Eric E Floranda
NPI 1942479803
$15,168.69
in general payments reported to CMS, 2019-2025
69 companies · $1,278 in 2025
The $1,278 reported for 2025 was more than what a typical Neuromuscular Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,082 · 2020: $1,471 · 2021: $2,494 · 2022: $2,690 · 2023: $2,205 · 2024: $1,949 · 2025: $1,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,230 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,229.98 |
| Education | $202.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,433.75 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Abbvie INC. | $1,291.93 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,197.23 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $1,108.07 | 2019-2025 | Ultomiris, Soliris |
| Biogen, INC. | $902.72 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Sk Life Science, INC. | $559.51 | 2020-2025 | Xcopri |
| Genzyme Corporation | $558.58 | 2019-2023 | |
| Lundbeck LLC | $524.97 | 2019-2025 | Vyepti, Rexulti |
| Genentech USA, INC. | $490.36 | 2019-2024 | Ocrevus, Ocrevus Zunovo |
| Amgen INC. | $375.55 | 2019-2025 | Uplizna |
| Lilly USA, LLC | $334.08 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Sunovion Pharmaceuticals INC. | $319.82 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $315.25 | 2022 | |
| Csl Behring | $314.19 | 2019-2025 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $311.37 | 2019-2022 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Floranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.